FILTER

FILTERED INTERVIEW RESULTS

Mining
Cote d’Ivoire
Ghana
MACIG

Jeff Quartermaine

CEO, PERSEUS MINING
Perseus Mining updates GBR on its three mines in West Africa.
Mining
Mali
MACIG

Larry Phillips

PRESIDENT AND CEO, COMPASS GOLD CORP
Compass Gold updates GBR on the exploration of its assets in Mali.
Mining
Ghana
MACIG

Peter Quarm

DIRECTOR, DUTYLEX
Dutylex explains the challenges of beginning a business distributing industrial lubricants in Ghana and West Arica more generally.
Mining
Guinea
Cote d’Ivoire
Mali
Senegal
Ghana
Burkina Faso
MACIG

Martin van Gemert

MANAGING DIRECTOR, MINCON WEST AFRICA
Mincon comments on its business with the mining sector in West Africa.
Mining
Peru
Canada
Namibia
Burkina Faso
MACIG

Ricus Grimbeek

PRESIDENT AND CEO, TREVALI
Trevali Mining examines the challenges of mining in the time of COVID-19 and how efforts to reduce costs have been rewarded.
Mining
Senegal
MACIG

Mike Brown

CEO, CHESSER RESOURCES
Chesser Resources is upbeat about its Diamba Sud gold resource in Eastern Senegal.
Mining
Guinea
MACIG

Danny Callow

CEO, AFRICAN GOLD GROUP (AGG)
African Gold Group explains its ambitions in West Africa where it’s Kobada gold mine is under construction.
Mining
Central African Republic
MACIG

Hon. Leopold Mboli Fatran

MINISTER OF MINES AND GEOLOGY, CENTRAL AFRICAN REPUBLIC (CAR)
GBR speaks to Leopold Mboli Fatran, Minister of Mines and Geology of Central African Republic concerning the challenges of developing the country’s resource industries.
Mining
Mali
MACIG

Danny Callow

COO, AFRICAN GOLD GROUP
African Gold Group explains its progress at its Kobada gold project in Mali as it advances towards production.
Mining
Mali
MACIG

Nana Bompeh Sangmuah

PRESIDENT & CEO, ROSCAN GOLD
Roscan Gold’s Kandiolé project is located in a highly-prospective district in Mali.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL